Skip to main content
Year
Paper
2021
Costa D, Simbrunner B, Jachs M, Hartl L, Bauer D, Paternostro R, Schwabl P, Scheiner B, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J Hepatol. 2021 Apr;74(4):819-828. doi: 10.1016/j.jhep.2020.10.004. Epub 2020 Oct 16.
Abstract: https://pubmed.ncbi.nlm.nih.gov/33075344/
2021
Schwabl P, Hambruch E, Budas GR, Supper P, Burnet M, Liles JT, Birkel M, Brusilovskaya K, Königshofer P, Peck-Radosavljevic M, Watkins WJ, Trauner M, Breckenridge DG, Kremoser C, Reiberger T. The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines. 2021 Jan 9;9(1):60. doi: 10.3390/biomedicines9010060.
Abstract: https://pubmed.ncbi.nlm.nih.gov/33435509/
2021
Costa D, Simbrunner B, Reiberger T. Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease". J Hepatol. 2021 Apr;74(4):1000-1001. doi: 10.1016/j.jhep.2021.01.026. Epub 2021 Jan 23.
Abstract: https://pubmed.ncbi.nlm.nih.gov/33497763/
2021
Simbrunner B, Costa D, Reiberger T. Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease". J Hepatol. 2021 Apr 20:S0168-8278(21)00233-6. doi: 10.1016/j.jhep.2021.03.027. Online ahead of print.
Abstract: https://pubmed.ncbi.nlm.nih.gov/33852949/
2020
Simbrunner B, Marculescu R, Scheiner B, Schwabl P, Bucsics T, Stadlmann A, Bauer DJM, Paternostro R, Eigenbauer E, Pinter M, Stättermayer AF, Trauner M, Mandorfer M, Reiberger T. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver Int. 2020 Jul;40(7):1713-1724. doi: 10.1111/liv.14498. Epub 2020 May 18.
Abstract: https://pubmed.ncbi.nlm.nih.gov/32358998/
2020
Brusilovskaya K, Königshofer P, Lampach D, Szodl A, Supper P, Bauer D, Beer A, Stift J, Timelthaler G, Oberhuber G, Podesser BK, Seif M, Zinober K, Rohr-Udilova N, Trauner M, Reiberger T, Schwabl P. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. United European Gastroenterol J. 2020 Dec;8(10):1174-1185. doi: 10.1177/2050640620944140. Epub 2020 Sep 2.
Abstract: https://pubmed.ncbi.nlm.nih.gov/32878579/
2020
Costa D, Simbrunner B, Jachs M, Hartl L, Bauer D, Paternostro R, Schwabl P, Scheiner B, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J Hepatol. 2021 Apr;74(4):819-828. doi: 10.1016/j.jhep.2020.10.004. Epub 2020 Oct 16.
Abstract: https://pubmed.ncbi.nlm.nih.gov/33075344/
2020
Sladky VC, Knapp K, Szabo TG, Braun VZ, Bongiovanni L, van den Bos H, Spierings DC, Westendorp B, Curinha A, Stojakovic T, Scharnagl H, Timelthaler G, Tsuchia K, Pinter M, Semmler G, Foijer F, de Bruin A, Reiberger T, Rohr-Udilova N, Villunger A. PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. EMBO Rep. 2020 Dec 3;21(12):e50893. doi: 10.15252/embr.202050893. Epub 2020 Nov 23.
Abstract: https://pubmed.ncbi.nlm.nih.gov/33225610/
2020
Simbrunner B, Semmler G, Stadlmann A, Scheiner B, Schwabl P, Paternostro R, Bucsics T, Bauer D, Eigenbauer E, Pinter M, Stättermayer AF, Quehenberger P, Marculescu R, Trauner M, Mandorfer M, Reiberger T. Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. Hepatol Int. 2020 Dec;14(6):1093-1103. doi: 10.1007/s12072-020-10112-3. Epub 2020 Dec 8.
Abstract: https://pubmed.ncbi.nlm.nih.gov/33289910/
2020
Wöran K, Semmler G, Jachs M, Simbrunner B, Maria Bauer DJ, Binter T, Pomej K, Stättermayer AF, Schwabl P, Bucsics T, Paternostro R, Lampichler K, Pinter M, Trauner M, Mandorfer M, Stift J, Reiberger T, Scheiner B. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. Clin Gastroenterol Hepatol. 2020 Dec 3:S1542-3565(20)31629-3. doi: 10.1016/j.cgh.2020.11.039. Epub ahead of print.
Abstract: https://pubmed.ncbi.nlm.nih.gov/33279774/
2020
Paternostro R, Pfeiffenberger J, Ferenci P, Stättermayer AF, Stauber RE, Wrba F, Longerich T, Lackner K, Trauner M, Ferlitsch A, Reiberger T, Weiss KH. Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. Liver Int. 2020 Apr;40(4):894-904. doi: 10.1111/liv.14368. Epub 2020 Jan 22.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31898387
2020
Brunner SB, Marculescu R, Scheiner B, Schwabl P, Bucsics T, Stadlmann A, Bauer DJM, Paternostro R, Eigenbauer E, Pinter M, Stättermayer AF, Trauner M, Mandorfer M, Reiberger T. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver Int. 2020 May 2. doi: 10.1111/liv.14498. Epub ahead of print.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/32358998
2019
Semmler G, Simbrunner B, Scheiner B, Schwabl P, Paternostro R, Bucsics T,Stättermayer AF, Bauer D, Pinter M, Ferenci P, Trauner M, Mandorfer M, Reiberger T. Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. JGastroenterol Hepatol. 2019 May 6. doi: 10.1111/jgh.14700. [Epub ahead of print]
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31062417